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Background

Results

• Since 2017, antimicrobial stewardship is a Centers
for Medicare & Medicaid Services (CMS) and The
Joint Commission (TJC) requirement for all acute
care hospitals, critical access hospitals, and
nursing care centers.

Figure 1. Cost savings associated with extended-infusion piperacillin/tazobactam in 2020
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• Given the current evidence supporting the
utilization of extended-infusion beta-lactams, the
system transitioned all its acute care facilities
within the region to extended-infusion
piperacillin/tazobactam (TZP) in March 2016

Results

• According to Bauer et al, the median length of
stay and hospital costs were significantly less for
patients admitted to the ICU who received
extended-infusion cefepime for bacteremia and/or
pneumonia
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• In 2020, the use of extended-infusion
piperacillin/tazobactam resulted in saving
$226,420 due to reduced administrations
compared to traditional infusion.
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• Decreased usage in antimicrobial agents that
have been considered as “restricted” by the
antimicrobial stewardship team resulted in
$182,837 saved in 2020.
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Table 1. Costs associated with hospital LOS in patients admitted to ICU on cefepime for Pseudomonas
pneumonia in 2020
Facility
Cost per LOS day
Mean LOS
Total LOS costs

Purpose

Hospital B

$5,773.1

17

$98,142.70

Hospital C

$3,611.16

2

$7,222.32

Hospital E

$8,392.71

27

$226,603.17

Hospital G

$5,594.49

31

$173,429.19

Hospital

$4,345.39

11

$47,799.29

Regional (n=25)

$5,543.37

18

$110,639.33

The purpose of this study was to evaluate financial
impact of a regional cost saving initiative by the
antimicrobial stewardship program for all acute care
facilities within the region, and identify potential
areas to reduce costs in the future.
The study looked at the following:
• Cost savings associated with reduced extendedinfusion piperacillin/tazobactam administrations in
2020.

Figure 2. Cost savings associated with reduced restricted agents usage between 2019-2020

• Difference in overall days of therapy and
antimicrobial-associated costs between 2019-2020.

• Potential cost savings associated with reduction in
hospital length of stay related to extended-infusion
cefepime use in ICU patients for the treatment of
Pseudomonas aeruginosa pneumonia.
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• Cost savings associated with decrease in use of
restricted antimicrobial agents between 2019-2020.
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• Multi-site retrospective review of eight inpatient
medical centers within the region of a large
integrated healthcare system
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2019 $23,583. $65,167. $25,470. $87,614. $69,897. $12,805. $6,842.0 $141,660 $21,086. $18,369. $12,461. $78,442. $8,989.0 $563,396
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Figure 3. Regional overall antimicrobial cost savings in 2020 (excluding remdesivir-associated)
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• Cost of each TZP premix bag was $10
• Cost of each hospitalized day in 2020, excluding
COVID-associated expenses was between
$3611.16 - $8392.71/day, depending on facility
• Cost difference between 2019 and 2020
associated with change in usage of pre-specified
“restricted” antimicrobial agents, as well as total
costs and days of therapy associated with
overall antimicrobial usage, excluding for
remdesivir, were collected through Tableau
reporting system
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• The initiative by the antimicrobial stewardship
program has resulted in substantial cost savings
for all covered inpatient facilities within the
region.
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• Overall, $616,178 was saved in antimicrobial
costs in 2020, after excluding costs attributed to
remdesivir, due to 19,775 days reduction in
overall days of therapy per 1000 patient days
between 2019 and 2020.
• For patients who are admitted to the ICU for
pneumonia due to P. aeruginosa requiring
cefepime administration, transition to extendedinfusion cefepime is anticipated to save between
$138,584.25-$1,385,842.5 depending on LOS
reduction between 1-10 days

Future Directions
Extended-infusion can optimize the timedependent property of beta-lactams without the
need for increased dose or more frequent
administrations, therefore minimizing risk for
development of adverse events. Given the
growing prevalence of multidrug-resistant
pathogens, optimizing the pharmacokinetic and
pharmacodynamic parameters of current
antibiotics to improve therapeutic efficacy is
prudent in improving clinical outcomes, while
maintaining antimicrobial sensitivity in the
community and minimizing unnecessary costs.
Based on current literature, the transition to
extended-infusion cefepime in the treatment of P.
aeruginosa pneumonia in patients requiring ICU
admission may reduce hospital costs.
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